Insider · CIK 0001965700
Deborah H. Charych
Files at SKYE (Skye Bioscience, Inc.). First filing -, latest -.
Deborah H. Charych files SEC Form 4 as director at SKYE (Skye Bioscience, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Deborah H. Charych has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Apr 2, 2026 |
| Feb 6, 2026 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Feb 9, 2026 |
| Feb 24, 2025 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Feb 26, 2025 |
| Oct 28, 2024 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Oct 30, 2024 |
Questions about Deborah H. Charych
Answered from the filings on this page, as of the latest one.
Is Deborah H. Charych buying or selling?
Deborah H. Charych has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Deborah H. Charych's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Deborah H. Charych has 0.
Where does Deborah H. Charych file Form 4?
Deborah H. Charych has filed Form 4 at SKYE (Skye Bioscience, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.